Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
NL0015436031
Tue, 28.03.2023
CureVac
CureVac Announces Voting Results of Extraordinary General Meeting
TÜBINGEN, Germany / BOSTON, USA – March 28, 2023 – CureVac N.V. (Nasdaq: CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced the voting results of the Company's e [ … ]
Tue, 28.03.2023
CureVac
CureVac Announces Voting Results of Extraordinary General Meeting
TÜBINGEN, Germany / BOSTON, USA – March 28, 2023 – CureVac N.V. (Nasdaq: CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced the voting results of the Company's e [ … ]
Fri, 10.02.2023
CureVac
CureVac Announces Closing of $250 million Follow-on Public Offering of Common Shares
TÜBINGEN, Germany/BOSTON, USA – February 10, 2023 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), announced today the closing of its fol [ … ]
Fri, 10.02.2023
CureVac
CureVac Announces Closing of $250 million Follow-on Public Offering of Common Shares
TÜBINGEN, Germany/BOSTON, USA – February 10, 2023 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), announced today the closing of its fol [ … ]
Wed, 08.02.2023
CureVac
CureVac Announces Pricing of Upsized Public Offering of Common Shares
TÜBINGEN, Germany/BOSTON, USA – February 7, 2023 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), announced today the pricing of 27,027,028 common sha [ … ]
Wed, 08.02.2023
CureVac
CureVac Announces Pricing of Upsized Public Offering of Common Shares
TÜBINGEN, Germany/BOSTON, USA – February 7, 2023 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), announced today the pricing of 27,027,028 common sha [ … ]
Mon, 06.02.2023
CureVac
CureVac Announces Proposed Public Offering of Common Shares
TÜBINGEN, Germany/BOSTON, USA – February 6, 2023 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), announced today that it intends to offer $200 million of its c [ … ]
Mon, 06.02.2023
CureVac
CureVac Announces Proposed Public Offering of Common Shares
TÜBINGEN, Germany/BOSTON, USA – February 6, 2023 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), announced today that it intends to offer $200 million of its c [ … ]
Wed, 01.02.2023
CureVac
CureVac Welcomes Myriam Mendila as New Chief Development Officer
Dr. Mendila joins CureVac as Chief Development Officer with more than 20 years of global industry experience
TÜBINGEN, Germany/ BOSTON, USA – February 1, 2023 – CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on [ … ]
Wed, 01.02.2023
CureVac
CureVac Welcomes Myriam Mendila as New Chief Development Officer
Dr. Mendila joins CureVac as Chief Development Officer with more than 20 years of global industry experience
TÜBINGEN, Germany/ BOSTON, USA – February 1, 2023 – CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on [ … ]